Related Experiment Video
Updated: Jun 3, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Connexin-26 is a key factor mediating gemcitabine bystander effect
Laura Garcia-Rodríguez1, Sandra Pérez-Torras, Meritxell Carrió
1Programa Gens i Malaltia, Centre de Regulació Genòmica. Dr. Aiguader, 88. 08003-Barcelona, Spain.
Molecular Cancer Therapeutics
|March 11, 2011
Summary
Connexin 26 (Cx26) facilitates gemcitabine's spread through gap junctions, enhancing its anticancer effects in pancreatic tumors. Upregulating Cx26 improves gemcitabine efficacy and promotes tumor regression.
Area of Science:
- Oncology
- Cell Biology
- Cancer Research
Background:
- Gemcitabine is a key chemotherapy drug for pancreatic cancer.
- Intercellular communication via gap junctions may influence drug efficacy.
- Connexins (Cx) form gap junctions, regulating cell-to-cell transport.
Purpose of the Study:
- To investigate the role of gap junctional intercellular communication (GJIC) in spreading gemcitabine cytotoxicity in pancreatic tumors.
- To determine the specific involvement of connexin 26 (Cx26) in gemcitabine's bystander effect.
Main Methods:
- Immunohistochemical analysis of pancreatic cancer biopsies for connexin expression (Cx26, Cx32, Cx43).
- Cx26 mRNA in situ hybridization to confirm Cx26 abundance.
- Cx26 knockdown and overexpression experiments in cancer cells.
- In vivo studies using mouse tumor models treated with gemcitabine.
Main Results:
- Pancreatic tumors showed increased Cx26 but decreased Cx32 and Cx43 expression.
- Cx26 levels correlated with GJIC capacity and gemcitabine's bystander cytotoxic effect.
- Cx26 knockdown reduced GJIC and gemcitabine bystander killing.
- Cx26 overexpression enhanced GJIC and gemcitabine's cytotoxic effect.
- Gemcitabine treatment delayed tumor progression in mice with high GJIC capacity.
- Overexpression of Cx26 led to significant tumor regression (50%) in vivo.
Conclusions:
- Cx26 plays a crucial role in the gap junction-mediated bystander cytotoxic effect of gemcitabine.
- Upregulation of Cx26 enhances gemcitabine's anticancer efficacy in pancreatic tumors.
- Targeting Cx26 could be a strategy to improve gemcitabine-based cancer therapy.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...